Colorectal Cancer
Conditions
Brief summary
Stage III colorectal cancer constitutes more than half of the colorectal patients, and the prognosis does not improve much recently although varies of adjuvant drugs have been tried. DC-CIK immunotherapy has been proved to improve survival in cancer patients, but its role in stage III colorectal cancer patients stains unclear. The investigators study will focus on the efficacy and safety of DC-CIK immunotherapy plus chemotherapy in the adjuvant treatment of stage III colorectal cancer, compared with chemotherapy alone.
Interventions
Sponsors
Sixth Affiliated Hospital, Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Stage III colon cancer * Undergone complete resection of primary tumor * Completed standard adjuvant chemotherapy * ECOG performancer status 0-2 * Adequate hematologic, hepatic and renal functions
Exclusion criteria
* HIV positive or other Immunodeficiency disease * Uncontrolled hypertension * History of recent cancers in the past 5 years * Patients with previous or concurrent malignancy or any anti-cancer therapy * Patients who were allergic to platinum drugs or fluorouracil * Pregnant patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 2 years |
| Side Effect | 6 month |
Contacts
Primary ContactXiaojian Wu, MD, PHD
Outcome results
None listed